For the first time cause of early cellular dysfunction in Alzheimer's disease recognized
TECHNICAL UNIVERSITY OF MUNICH
Corporate Communications Center
This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35644/
High resolution images: https://mediatum.ub.tum.de/1516971
Cause of early cellular dysfunction in Alzheimer's disease recognized for the first time
Direct toxic action of beta-amyloid identified
Hyperactive neurons in specific areas of the brain are believed to be an early perturbation in Alzheimer's disease. For the first time, a team from the Technical University of Munich (TUM) was able to explain the reasons and mechanisms underlying this early and therefore important neuronal dysfunction. They found that the excitatory neurotransmitter glutamate persists for too long near active neurons. This causes a pathological overstimulation of those neurons - most likely contributing critically to impaired learning and memory loss in Alzheimer's patients.
The brains of Alzheimer's patients who have already developed clinical symptoms contain large clumps of the protein beta-amyloid, known as plaques. Many therapeutic approaches focus on removing plaques, but such attempts have met with only limited success to date.
"It's crucial that we detect and treat the disease much earlier. We therefore focused on hyperactive neurons, which occur at a very early stage - long before patients develop memory loss," explains Professor Arthur Konnerth, Hertie Senior Professor of Neuroscience at the TUM. As a consequence of hyperactivation, connected neurons in the circuits constantly receive false signals, leading to impairments in signal processing.
Together with his doctoral student Benedikt Zott and the entire research team, Konnerth succeeded in identifying the cause and trigger of this early disturbance in the brain. The discovery may open the way to new therapeutic approaches. The study appeared in the journal Science.
Beta-amyloid blocks glutamate re-uptake
Neurons use chemicals called neurotransmitters to communicate with each other. Glutamate, one of the most important of these chemicals, serves to activate connected neurons. Glutamate is released at the connecting site between two neurons, called synapse, and than rapidly removed to allow the transmission of the next signal. This removal involves so-called active pump molecules as well as a passive transport of glutamate along nearby membranes.
The researchers discovered that high concentrations of glutamate persisted too long in the synaptic cleft of hyperactive neurons. This was due to the action of beta-amyloid molecules, which blocked glutamate transport out of the synaptic cleft. The team tested the mechanism using beta-amyloid molecules from patient samples and by using various mouse models obtaining similar results with both approaches.
Indication for treatment strategies at early stages
The team was also intrigued to discover that the neurotransmitter blockade was mediated by an early soluble form of beta-amyloid and not by the plaques. Beta-amyloid occurs initially as a single molecule form, or monomer, and then aggregates to double-molecule forms (dimers) and larger chains resulting, eventually, in plaques. The researchers found that glutamate blockade is caused by the soluble dimers.
"Our data provide clear evidence for a rapid and direct toxic effect of a particular beta-amyloid type, the dimers. We were even able to explain this mechanism," as Benedict Zott, first author of the study, outlined. The researchers now want to use this knowledge to further improve their understanding of the cellular mechanisms of Alzheimer's and, thus, to support the development of strategies for treatment at early stages of the disease.
Benedikt Zott, Manuel M. Simon, Wei Hong, Felix Unger, Hsing-Jung Chen-Engerer, Matthew P. Frosch, Bert Sakmann, Dominic M. Walsh, Arthur Konnerth, A vicious cycle of b amyloid-dependent neuronal hyperactivation, Science, August 9, 2019; DOI: 10.1126/science.aay0198
Download high-resolution images:
Professor Arthur Konnerth is a member of the cluster of excellence "SyNergy - Munich Cluster for Systems Neurology", which studies how neurological diseases such as Alzheimer's disease and multiple sclerosis develop. Because the nervous system is extremely complex, the development of neurodegenerative diseases is influenced by numerous processes. A new interdisciplinary approach, system neurology, lies at the heart of the Munich research. The cluster has been funded by the Excellence Initiative since 2012. In addition to the joint applicants TUM and LMU, the German Center for Neurodegenerative Diseases, Helmholtz Zentrum München and the Max Planck Institutes of Biochemistry, Neurobiology and Psychiatry are also involved in SyNergy.
- Profile of Professor Arthur Konnerth http://www.professoren.tum.de/en/konnerth-arthur/ - Institute of Neuroscience of the TUM http://www.ifn.me.tum.de/new/konnerth.php - Website of the SyNergy Cluster https://www.synergy-munich.de/index.html
Prof. Arthur Konnerth
Hertie Senior Professor of Neurosciences
Institute of Neuroscience of the Technical University of Munich
The Technical University of Munich (TUM) is one of Europe's leading research universities, with around 550 professors, 41,000 students, and 10,000 academic and non-academic staff. Its focus areas are the engineering sciences, natural sciences, life sciences and medicine, combined with economic and social sciences. TUM acts as an entrepreneurial university that promotes talents and creates value for society. In that it profits from having strong partners in science and industry. It is represented worldwide with the TUM Asia campus in Singapore as well as offices in Beijing, Brussels, Cairo, Mumbai, San Francisco, and São Paulo. Nobel Prize winners and inventors such as Rudolf Diesel, Carl von Linde, and Rudolf Mößbauer have done research at TUM. In 2006, 2012 and 2019 it won recognition as a German "Excellence University." In international rankings, TUM regularly places among the best universities in Germany. www.tum.de